I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Metabolic syndrome (MetS) has become a global health issue and is characterized by abdominal adiposity, insulin resistance, essential hypertension (EH), dyslipidemia, elevated glucose plasma levels, and so on.\[[@ref1]\] MetS is considered as a risk factor for cardiovascular disease (CVD). The presence of MetS leads to a threefold increase in CVD risk\[[@ref2]\] and contributes to all-cause mortality.\[[@ref3]\] The study has reported that EH was one of the key features of MetS,\[[@ref4]\] and the presence of MetS in EH patients was higher than in the general population.\[[@ref5]\] It has been reported that MetS occurred after the onset of endothelial dysfunction, which resulted in atherosclerosis. Atherosclerosis is usually identified before other clinical manifestations of CVD.\[[@ref6]\] Gender is a significant effect modifier for MetS-related cardiovascular mortality.\[[@ref1]\] A previous study demonstrated that the risk of CVD attributed to MetS was more than 2-fold higher in women compared to men. In addition, more than half of all cardiovascular events in women were related to MetS.\[[@ref7]\] CVD is one of the main causes of death among women in the world.\[[@ref8]\] Therefore, the identification and management of MetS are vital for the prevention of CVD.

Traditional Chinese medicine has become one of the fastest growing health-care choices. *Astragalus membranaceus* (AM) includes multiple active components and has various protective effects on angiocarpy.\[[@ref9][@ref10]\] The various protective effects of AM have been reported in previous studies. Therefore, this study aimed to evaluate the effects of different doses of AM on ventricular diastolic function in postmenopausal hypertensive women with MetS.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the Ethics Committee of Lanzhou University Second Hospital (No. 20101024038). Informed written consent was obtained from all patients prior to their enrollment in this study.

Experimental patients {#sec2-2}
---------------------

This was a prospective, open-labeled, parallel, randomized controlled trial which adopted simple randomization and was realized by a computer random number table. According to previous studies and accounting for a lost to follow-up rate of 10%, the following formula\[[@ref11]\] was used to calculate the sample size: ![](CMJ-131-516-g001.jpg). And, the sample of this study was determined to be 159 eventually. This research study was registered under the Chinese Clinical Trial Register Website (No. ChiCTR-TRC-11001747).

A total of 159 postmenopausal hypertensive patients with MetS who were less than 60 years old were enrolled from the Outpatient Department of Cardiovascular Medicine, the Inpatient Department of Cardiovascular Medicine, the Outpatient Department of Endocrinology, the Inpatient Department of Endocrinology, the Outpatient Department of Diabetes, and the Inpatient Department of Diabetes between March 2014 and April 2015. Participants were divided into three groups: control group (received conventional medical treatment), AM Group 1 (received AM capsules at 5 g/d in addition to conventional medical treatment), and AM Group 2 (received AM capsules at 10 g/d in addition to conventional medical treatment). The patients were treated for 12 months. They finished the complete and necessary examinations and tests before and after 12 months' treatment. Moreover, all patients were followed up each month by telephone.

The inclusion criteria were as follows: EH and asymptomatic left ventricular diastolic dysfunction (LVDD) was established when (1) systolic blood pressure (SBP) ≥140 mmHg; (2) diastole blood pressure (DBP) ≥90 mmHg; (3) EH patients with or without antihypertensive treatments; or (4) patients had previously been diagnosed with EH. MetS was diagnosed according to the Third Report of the National Cholesterol Education Program Adult Treatment Panel,\[[@ref12]\] which defines MetS as hypertension and the presence of any two of the following: (1) waist circumference (WC) \>102 cm in men and \>88 cm in women; (2) triglycerides (TGs) ≥1500 mg/L (1.69 mmol/L); (3) high-density lipoprotein-cholesterol (HDL-c) \<400 mg/L (1.04 mmol/L) in men and \<500 mg/L (1.29 mmol/L) in women; and (4) fasting plasma glucose (FPG) ≥1100 mg/L (6.10 mmol/L).

The exclusion criteria were as follows: patients who had been diagnosed with secondary hypertension, coronary disease, heart failure, arterial fibrillation, previous myocardial infarction, previous stroke, malignant disease, kidney or liver failure, neoplastic disease, severe neurological diseases, severe metabolic or organic decompensation, or other chronic physical or cerebrovascular diseases, or patients who did not agree to sign the informed consent form.

Data collection {#sec2-3}
---------------

The doctors, who have received research training, collected information on the sociodemographic characteristics and medical history using the questionnaires.

Anthropometric measurements {#sec2-4}
---------------------------

Anthropometric measurements including height, body weight, and waist and hip circumferences were taken when the patients were barefoot and wearing light clothing. Body mass index (BMI) was calculated as the ratio of weight (kg) to the square of the height (m^2^). WC was measured at the middle between the 10^th^ rib and the iliac crest with the participants standing and wearing light clothing. The tape was snug and parallel to the floor but was held without skin compression.\[[@ref13]\] The hip circumference was measured at the widest level over the greater trochanters, and the waist-to-hip ratio (WHR) was calculated by dividing the WC (cm) by the hip circumference (cm). All measurements were taken thrice, and the means were recorded.

Blood pressure measurement {#sec2-5}
--------------------------

Blood pressure in the right arm was taken by trained doctors with the participants in a sitting position and having rested for at least 10 min; a sphygmomanometer with an appropriate cuff size and stethoscope were used in accordance with the recommendations of the American Heart Association.\[[@ref14]\] SBP and DBP were taken at the 1^st^ and 5^th^ Korotkoff sounds, respectively. At each visit, the blood pressure was recorded as the mean of two measurements that were within 5 mmHg. Participants were asked to avoid caffeine, exercise, and smoking for at least 30 min prior to measurement.

Biochemical examination {#sec2-6}
-----------------------

Venous blood was collected from the antecubital vein between 08:00 and 09:30 a.m. after 8--12 h overnight fast. The blood levels of total cholesterol (TC) were measured using the cholesterol oxidase enzymatic method, an enzymatic colorimetric method; HDL-c was determined after dextran sulfate-magnesium chloride precipitation of HDL; TG was measured enzymatically after the hydrolyzation of glycerol; and FPG was determined by the glucose oxidase enzymatic method. Aspartate aminotransferase, alanine transaminase, and creatinine (Cr) were measured by automatic biochemical analyzer. Low-density lipoprotein-cholesterol (LDL-c) was calculated using the Friedewald formula. White blood cell, red blood cell, and blood platelet counts were determined by the impedance method, and hemoglobin was measured using spectrocolorimetry. All the tests were performed in the Central Laboratory of Lanzhou University Second Hospital using an ELAN autoanalyzer (Eppendorf, Germany). For quality control measures, this laboratory meets the criteria of the National Standard Laboratory (a WHO collaboration center in Tehran). All biochemical analyses were done using Beckman reagent kits on a Beckman SYNCHRON CX7 Analyzer (Beckman, Fullerton, CA, USA).

Echocardiography {#sec2-7}
----------------

According to the American Society of Echocardiography\'s guidelines,\[[@ref15]\] echocardiographic measurements were performed by one experienced doctor in a supine position with participants in the left lateral decubitus position and using a General Electric Vivid 7 Expert (GE Vingmed Ultrasound, Horten, Norway) transthoracic echocardiography machine with a 3.5-MHz transducer. Measurements were performed for three consecutive heart beats, and three consecutive cycles were averaged for every parameter. All patients were evaluated by two-dimensional, pulsed wave Doppler echocardiography and tissue color Doppler imaging.

Cardiac structure and systolic function measurement {#sec2-8}
---------------------------------------------------

Left atrial diameter (LAd) was measured using the M-mode in the parasternal short axis at the level of the aortic valve. Left ventricular end-diastolic dimension (LVEDd), interventricular septal thickness (IVST), and left ventricular posterior wall thickness (LVPWT) were measured using the two-dimensional (2D)-targeted M-mode at end diastole. Left ventricular end-systolic dimension (LVESd) and LA dimensions were obtained using the 2D-targeted M-mode at end systole. Left ventricular (LV) end-diastolic volumes and end-systolic volumes were measured from an apical two- and four-chamber view using the modified Simpson\'s method. Left ventricular mass (LVM) was calculated using the Devereux formula:\[[@ref15]\]1.04 × (\[LVEDd + IVST + LVPWT\]^3^ -- LVEDd^3^) -- 13.6. The LVMI index (LVMI) was determined by using the ASE-recommended formula:\[[@ref16]\] LVMI (g/m^2^) = (1.04 × \[(IVST + LVEDd + LVPWT)^3^ -- LVEDd^3^\] -- 13.6)/body surface area (BSA). BSA was calculated using the Du Bois formula:\[[@ref17]\] BSA = 0.007148 (height)^0.725^ (weight)^0.425^, with height measured in meters and weight measured in kilograms. LV systolic function was determined by the LV ejection fraction (EF), which was calculated according to the modified Simpson\'s formula\[[@ref18]\] and Simpson\'s biplane method. The EF and fractional shortening (FS) were calculated by using Teichholz\'s M-mode formula and were all measured in the parasternal long-axis view. Stroke volume (SV) was calculated as the product of the velocity-time integral (VTI) and the radius of the aortic cross-sectional area (SV = *r*^2^πVTI). Cardiac output (L/min) was calculated as the product of heart rate and SV divided by 1000.\[[@ref19]\]

Diastolic function measurement {#sec2-9}
------------------------------

Diastolic function was measured using pulse Doppler transmitral velocities, pulmonary venous velocities, and tissue Doppler measurements. Mitral inflow was determined by continuous and pulse wave Doppler echocardiography at the tips of the mitral leaflets. Early diastolic mitral peak flow velocity (E), late diastolic mitral peak flow velocity (A), E/A ratio, and deceleration time (DT) of early diastolic transmitral flow were measured from the apical four-chamber view. Early diastolic mitral annular velocity (E') and late diastolic mitral annular velocity (A') were measured at the septal and lateral mitral annuli by pulsed-wave tissue Doppler. Then, the E/E' ratio was calculated, which has been shown to correlate with LV filling pressures. Aortic and mitral regurgitations were graded on a color Doppler. At least three consecutive cycles were recorded. The position of the sample volume for velocity and strain measurements was manually positioned in the myocardium throughout the cardiac cycle.

Statistical analysis {#sec2-10}
--------------------

Statistical analysis was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Based on the normal distribution, continuous variables were compared by Student\'s *t*-test or analysis of variance (ANOVA). Continuous variables were expressed as mean ± standard deviation (SD)or percentages. Multiple linear regression analysis was performed for interactions between the components of MetS and the related parameters of LVDD. Age, BMI, WC, WHR, SBP, DBP, TC, TG, HDL-c, LDL-c, and FPG were entered into the multiple linear regression model as independent variables. However, they were removed in a reverse stepwise manner if the associated interaction *P* ≥ 0.05. A *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Baseline characteristics of all participants {#sec2-11}
--------------------------------------------

For this 12-month study, 159 postmenopausal women were initially qualified. Five patients were excluded from this study because they could not complete the follow-up on time. Finally, a total of 154 patients completed the entire study and were subjected to further analysis. The baseline characteristics and antihypertensive drug use of all patients with metabolic diseases are shown in [Table 1](#T1){ref-type="table"}. The mean ages of the control group, AM Group 1, and AM Group 2 were 53.0 ± 4.8 years, 53.8 ± 5.1 years, and 53.3 ± 5.0 years, respectively. No significant differences in all characteristics were observed at baseline among the three groups (all *P* \> 0.05; [Table 1](#T1){ref-type="table"}).

###### 

Basic characteristics of all postmenopausal hypertensive patients with metabolic syndrome in this study (*N* = 154)

  Items                            Control group (*n* = 52)   AM Group 1 (*n* = 49)   AM Group 2 (*n* = 53)   *F*     *P*
  -------------------------------- -------------------------- ----------------------- ----------------------- ------- -------
  Age (years)                      53.0 ± 4.8                 53.8 ± 5.1              53.3 ± 5.0              0.343   0.710
  Height (cm)                      160.0 ± 4.1                159.6 ± 4.1             160.0 ± 4.0             0.152   0.859
  Elevated plasma glucose levels   26 (50.0)                  28 (57.1)               31 (58.5)               0.875   0.646
  Dyslipidemia                     31 (59.6)                  34 (69.4)               34 (64.2)               1.050   0.592
  Abdominal adiposity              37 (71.2)                  31 (63.3)               35 (66.0)               0.735   0.693
  Medications                                                                                                         
   ACEI                            20 (38.5)                  17 (34.7)               18 (34.0)               0.264   0.876
   ARB                             8 (15.4)                   6 (12.2)                7 (13.2)                0.224   0.894
   CCB                             17 (32.7)                  15 (30.6)               15 (28.3)               0.239   0.887
   Diuretic                        11 (21.2)                  11 (22.4)               13 (24.5)               0.173   0.917
   Beta blocker                    21 (40.4)                  21 (42.9)               23 (43.4)               0.110   0.946
   ACEI + CCB                      8 (15.4)                   7 (14.3)                8 (15.1)                0.026   0.987
   ARB + CCB                       5 (9.6)                    11 (22.4)               11 (20.8)               3.454   0.178
   ACEI + diuretic                 9 (17.3)                   7 (14.3)                10 (18.9)               0.391   0.822
   ARB + diuretic                  7 (13.5)                   5 (10.2)                6 (11.3)                0.270   0.874

The data were shown as mean ± SD or *n* (%). ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; AM: *Astragalus membranaceus*; CCB: Calcium channel blocker; SD: Standard deviation.

Metabolic index analyses {#sec2-12}
------------------------

The metabolic indices of the study population are shown in [Table 2](#T2){ref-type="table"}. Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all *P* \> 0.05). There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all *P* \> 0.05).

###### 

Comparisons of clinical characteristics and metabolic indexes among three groups before and after treatment

  Items                    Control group (*n* = 52)           AM Group 1 (*n* = 49)                                                                                                               
  ------------------------ ---------------------------------- ------------------------------------- --------------------- ---------------------- --------------------- ---------------- --------- -------
  WBC (×10^9^/L)           6.28 ± 1.23                        6.58 ± 1.13                           −1.531                0.132                  6.19 ± 1.18           6.19 ± 1.00      −0.017    0.986
  RBC (×10^12^/L)          4.57 ± 0.44                        4.58 ± 0.41                           −0.380                0.706                  4.74 ± 0.38           4.72 ± 0.36      0.489     0.627
  PLT (×10^9^/L)           217.10 ± 38.07                     214.33 ± 44.59                        1.095                 0.279                  210.06 ± 38.93        209.92 ± 41.29   0.062     0.951
  HGB (g/L)                131.73 ± 7.60                      132.44 ± 6.71                         −1.123                0.267                  133.25 ± 8.66         133.47 ± 8.13    −0.551    0.584
  WC (cm)                  92.15 ± 5.04                       92.27 ± 4.30                          −0.374                0.710                  91.82 ± 4.68          91.75 ± 4.36     0.235     0.815
  Hip circumference (cm)   106.46 ± 4.88                      106.75 ± 4.62                         −1.111                0.272                  106.51 ± 5.15         106.69 ± 4.64    0.075     0.940
  WHR                      0.87 ± 0.02                        0.86 ± 0.02                           0.312                 0.749                  0.86 ± 0.02           0.86 ± 0.02      0.163     0.879
  Weight (kg)              66.83 ± 4.06                       66.71 ± 3.69                          0.784                 0.437                  66.52 ± 4.35          66.66 ± 4.06     −0.823    0.415
  BMI (kg/m^2^)            26.10 ± 1.53                       26.06 ± 1.43                          0.737                 0.465                  26.09 ± 1.18          26.15 ± 1.16     −0.914    0.365
  CR (µmmol/L)             73.90 ± 5.79                       75.20 ± 3.97                          −1.811                0.076                  73.24 ± 7.83          73.89 ± 6.65     −1.161    0.251
  UA (µmmol/L)             368.06 ± 38.77                     375.89 ± 38.12                        −1.989                0.052                  385.80 ± 46.60        383.84 ± 42.44   0.682     0.499
  TC (mmol/L)              4.87 ± 0.43                        4.84 ± 0.42                           0.721                 0.478                  4.83 ± 0.31           4.88 ± 0.24      −1.460    0.151
  TG (mmol/L)              2.25 ± 0.39                        2.28 ± 0.33                           −1.264                0.212                  2.34 ± 0.49           2.38 ± 0.39      −1.167    0.249
  HDL-c (mmol/L)           1.77 ± 0.39                        1.74 ± 0.32                           0.815                 0.419                  1.64 ± 0.34           1.67 ± 0.31      −0.979    0.333
  LDL-c (mmol/L)           2.57 ± 0.56                        2.59 ± 0.46                           −0.403                0.688                  2.56 ± 0.67           2.65 ± 0.67      −1.386    0.172
  GLU (mmol/L)             6.72 ± 0.55                        6.78 ± 0.43                           −1.816                0.075                  6.60 ± 0.45           6.68 ± 0.43      −1.913    0.062
  BUN (mmol/L)             6.08 ± 1.00                        6.21 ± 0.82                           −1.907                0.062                  6.44 ± 0.95           6.49 ± 0.80      −0.947    0.348
  ALT (U/L)                39.96 ± 10.67                      41.12 ± 8.26                          −0.818                0.417                  41.78 ± 11.92         40.82 ± 9.89     0.456     0.650
  AST (U/L)                37.73 ± 10.86                      38.89 ± 8.43                          −0.661                0.802                  39.59 ± 7.88          42.12 ± 8.00     −1.590    0.118
  SBP (mmHg)               133.23 ± 7.84                      134.62 ± 6.56                         −1.486                0.143                  135.55 ± 8.05         134.37 ± 8.66    1.448     0.154
  DBP (mmHg)               79.37 ± 7.77                       78.40 ± 5.42                          1.773                 0.082                  77.27 ± 7.45          76.69 ± 6.71     1.324     0.192
  BNP (pg/ml)              84.78 ± 34.85                      84.30 ± 31.32                         0.177                 0.860                  84.48 ± 34.99         84.21 ± 31.75    0.094     0.925
                                                                                                                                                                                                  
  **Items**                **AM Group 2 (*n* = 53)**          **Control group versus AM Group 1**                                                                                                 
                                                                                                                                                                                                  
  **Before treatment**     **After treatment**                ***t***                               ***P***               **Before treatment**   **After treatment**                              
                                                                                                                                                                                                  
  ***t***                  ***P***                            ***t***                               ***P***                                                                                       
                                                                                                                                                                                                  
  WBC (×10^9^/L)           6.57 ± 1.18                        6.47 ± 1.25                           0.918                 0.363                  0.380                 0.705            1.823     0.071
  RBC (×10^12^/L)          4.66 ± 0.55                        4.65 ± 0.49                           0.405                 0.687                  −2.067                0.068            −1.812    0.073
  PLT (×10^9^/L)           203.64 ± 48.91                     206.51 ± 49.19                        −1.309                0.196                  0.918                 0.361            0.515     0.608
  HGB (g/L)                133.76 ± 8.34                      133.83 ± 8.53                         −0.154                0.878                  −0.935                0.352            −0.694    0.489
  WC (cm)                  93.32 ± 4.83                       93.13 ± 3.11                          0.375                 0.710                  0.343                 0.733            0.608     0.544
  Hip circumference (cm)   107.60 ± 4.70                      107.72 ± 3.77                         0.114                 0.909                  −0.008                0.994            0.337     0.737
  WHR                      0.87 ± 0.02                        0.87 ± 0.02                           0.296                 0.764                  1.027                 0.307            0.597     0.552
  Weight (kg)              67.04 ± 4.32                       66.86 ± 4.16                          0.697                 0.489                  0.365                 0.716            0.056     0.955
  BMI (kg/m^2^)            26.18 ± 1.20                       26.11 ± 1.22                          0.665                 0.509                  0.040                 0.968            −0.362    0.718
  CR (µmmol/L)             72.57 ± 7.99                       73.85 ± 7.08                          −1.683                0.098                  0.483                 0.630            1.211     0.229
  UA (µmmol/L)             385.19 ± 50.30                     390.66 ± 54.42                        −1.355                0.181                  −2.084                0.052            −0.992    0.324
  TC (mmol/L)              4.76 ± 0.44                        4.80 ± 0.41                           −1.800                0.078                  1.960                 0.053            1.050     0.296
  TG (mmol/L)              2.31 ± 0.48                        2.30 ± 0.40                           0.204                 0.839                  −1.082                0.282            −1.362    0.176
  HDL-c (mmol/L)           1.75 ± 0.35                        1.77 ± 0.27                           −0.672                0.505                  1.871                 0.064            1.262     0.210
  LDL-c (mmol/L)           2.67 ± 0.53                        2.72 ± 0.40                           −1.389                0.171                  0.109                 0.913            −0.572    0.569
  GLU (mmol/L)             6.78 ± 0.44                        6.77 ± 0.40                           0.006                 0.995                  1.171                 0.244            1.229     0.222
  BUN (mmol/L)             6.31 ± 1.02                        6.42 ± 0.92                           −1.819                0.075                  −1.829                0.070            −1.744    0.084
  ALT (U/L)                38.64 ± 10.85                      41.32 ± 8.98                          −1.641                0.107                  −0.807                0.422            0.165     0.869
  AST (U/L)                37.77 ± 10.22                      40.13 ± 9.75                          −1.463                0.149                  −0.981                0.329            −1.977    0.051
  SBP (mmHg)               133.51 ± 7.71                      132.96 ± 6.51                         0.726                 0.471                  −1.468                0.145            0.163     0.871
  DBP (mmHg)               77.40 ± 8.61                       77.17 ± 7.56                          0.389                 0.699                  1.385                 0.169            1.413     0.161
  BNP (pg/ml)              85.42 ± 33.29                      84.20 ± 29.40                         0.437                 0.664                  0.043                 0.965            0.014     0.989
                                                                                                                                                                                                  
  **Items**                **AM Group 1 versus AM Group 2**   **Control group versus AM Group 2**                                                                                                 
                                                                                                                                                                                                  
  **Before treatment**     **After treatment**                **Before treatment**                  **After treatment**                                                                           
                                                                                                                                                                                                  
  ***t***                  ***P***                            ***t***                               ***P***               ***t***                ***P***               ***t***          ***P***   
                                                                                                                                                                                                  
  WBC (×10^9^/L)           −1.649                             0.102                                 1.823                 0.219                  −1.254                0.213            0.469     0.640
  RBC (×10^12^/L)          0.832                              0.408                                 −1.812                0.437                  −0.940                0.349            −0.812    0.419
  PLT (×10^9^/L)           0.730                              0.467                                 0.515                 0.707                  1.571                 0.119            0.853     0.396
  HGB (g/L)                −0.303                             0.763                                 −0.694                0.828                  −1.299                0.197            −0.926    0.357
  WC (cm)                  −1.596                             0.114                                 0.608                 0.065                  −1.219                0.226            −1.183    0.239
  Hip circumference (cm)   −1.348                             0.181                                 0.337                 0.118                  −1.375                0.172            −1.176    0.242
  WHR                      −1.363                             0.176                                 0.597                 0.434                  −0.262                0.794            −0.154    0.878
  Weight (kg)              −0.597                             0.552                                 0.056                 0.807                  −0.254                0.800            −0.204    0.839
  BMI (kg/m^2^)            −0.350                             0.727                                 −0.362                0.861                  −0.268                0.789            −0.204    0.839
  CR (µmmol/L)             0.426                              0.671                                 1.211                 0.972                  0.974                 0.332            1.210     0.229
  UA (µmmol/L)             0.063                              0.950                                 −0.992                0.484                  −1.952                0.054            −1.609    0.111
  TC (mmol/L)              1.411                              0.161                                 1.050                 0.233                  3.025                 0.130            1.868     0.065
  TG (mmol/L)              0.323                              0.747                                 −1.362                0.319                  −0.740                0.461            −0.275    0.784
  HDL-c (mmol/L)           −1.652                             0.102                                 1.262                 0.074                  0.312                 0.756            −0.430    0.668
  LDL-c (mmol/L)           −0.931                             0.354                                 −0.572                0.544                  −0.911                0.365            −1.565    0.121
  GLU (mmol/L)             −1.945                             0.055                                 1.229                 0.231                  −0.563                0.575            0.087     0.931
  BUN (mmol/L)             0.659                              0.512                                 −1.744                0.693                  −1.150                0.253            −1.257    0.212
  ALT (U/L)                1.390                              0.168                                 0.165                 0.788                  0.628                 0.531            −0.122    0.903
  AST (U/L)                1.000                              0.320                                 −1.977                0.265                  −0.021                0.983            −0.701    0.485
  SBP (mmHg)               1.308                              0.194                                 0.163                 0.354                  −0.184                0.855            1.296     0.198
  DBP (mmHg)               −0.082                             0.935                                 1.413                 0.738                  1.230                 0.222            0.959     0.340
  BNP (pg/ml)              −0.138                             0.890                                 0.002                 0.998                  −0.095                0.925            0.017     0.986

The data were shown as mean ± SD. WBC: White blood cell; RBC: Red blood cell; PLT: Platelet; HGB: Hemoglobin; WC: Waist circumference; WHR: Waistto-hip ratio; BMI: Body mass index; CR: Creatinine; UA: Uric acid; TC: Total cholesterol; TG: Triglyceride; HDL-c: High-density lipoprotein-cholesterol; LDL-c: Low-density lipoprotein-cholesterol; GLU: Glucose; BUN: Blood urea nitrogen; ALT: Alanine transaminase; AST: Aspartate aminotransferase; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BNP: B-type natriuretic peptide; SD: Standard deviation; AM: *Astragalus membranaceus*.

No significant differences between baseline and 12 months after treatment were observed for weight, GLU, BMI, WC, WHR, UA, TC, TG, HDL-c, LDL-c, DBP, or BNP in the three groups (all *P* \> 0.05).

Cardiac structure and systolic function analyses {#sec2-13}
------------------------------------------------

As shown in [Table 3](#T3){ref-type="table"}, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all *P* \> 0.05).

###### 

Comparisons of cardiac structure and left ventricular systolic function among three groups before and after treatments

  Items                  Control group (*n* = 52)           AM Group 1 (*n* = 49)                                                                                                               
  ---------------------- ---------------------------------- ------------------------------------- --------------------- ---------------------- --------------------- ---------------- --------- -------
  LAd (mm)               27.56 ± 2.64                       27.94 ± 2.15                          −1.694                0.096                  28.44 ± 2.99          28.52 ± 2.09     −0.250    0.804
  LVEDd (mm)             44.60 ± 2.07                       44.59 ± 1.89                          0.038                 0.970                  44.49 ± 1.78          44.70 ± 1.44     −0.748    0.458
  LVESd (mm)             29.81 ± 2.67                       29.52 ± 2.28                          0.353                 0.725                  29.91 ± 2.92          29.51 ± 2.95     0.781     0.439
  IVST (mm)              9.61 ± 0.91                        9.61 ± 0.89                           0.016                 0.987                  9.47 ± 0.82           9.42 ± 0.80      0.311     0.757
  LVPWT (mm)             9.47 ± 0.77                        9.26 ± 0.94                           1.641                 0.107                  9.36 ± 0.74           9.18 ± 0.88      0.971     0.336
  LVM (g)                142.29 ± 19.94                     140.25 ± 21.65                        0.770                 0.445                  138.78 ± 15.14        137.84 ± 17.74   0.256     0.799
  LVMI (g/m^2^)          84.23 ± 11.75                      83.07 ± 12.32                         0.722                 0.474                  82.48 ± 9.98          81.71 ± 10.49    0.351     0.727
  EDV (ml)               109.79 ± 9.68                      109.90 ± 10.78                        −1.403                0.167                  109.00 ± 12.31        110.18 ± 12.89   −1.032    0.307
  ESV (ml)               42.83 ± 5.18                       42.52 ± 6.52                          −1.204                0.234                  43.67 ± 6.85          43.45 ± 7.31     −0.452    0.653
  SV (ml)                66.96 ± 7.92                       67.39 ± 8.79                          −1.279                0.207                  65.33 ± 7.93          66.74 ± 7.15     −1.300    0.200
  EF (%)                 60.72 ± 2.14                       60.56 ± 2.67                          0.648                 0.520                  60.48 ± 3.00          60.60 ± 3.22     −0.228    0.821
  FS (%)                 32.47 ± 5.45                       32.62 ± 5.79                          −0.379                0.706                  32.66 ± 4.25          33.33 ± 5.32     −1.142    0.259
                                                                                                                                                                                                
  **Items**              **AM Group 2 (*n* = 53)**          **Control group versus AM Group 1**                                                                                                 
                                                                                                                                                                                                
  **Before treatment**   **After treatment**                ***t***                               ***P***               **Before treatment**   **After treatment**                              
                                                                                                                                                                                                
  ***t***                ***P***                            ***t***                               ***P***                                                                                       
                                                                                                                                                                                                
  LAd (mm)               28.55 ± 2.54                       28.42 ± 2.07                          0.528                 0.600                  −1.568                0.120            −1.372    0.173
  LVEDd (mm)             44.45 ± 1.94                       44.97 ± 1.88                          −1.423                0.161                  0.291                 0.771            −0.345    0.731
  LVESd (mm)             29.88 ± 2.91                       29.71 ± 2.90                          −1.740                0.088                  0.222                 0.825            0.441     0.660
  IVST (mm)              9.52 ± 0.88                        9.51 ± 0.73                           0.084                 0.933                  0.800                 0.426            1.111     0.269
  LVPWT (mm)             9.42 ± 0.72                        9.14 ± 0.82                           1.777                 0.081                  0.758                 0.451            0.429     0.669
  LVM (g)                139.90 ± 17.53                     139.63 ± 17.49                        0.076                 0.940                  0.992                 0.324            0.610     0.543
  LVMI (g/m^2^)          81.91 ± 10.29                      82.17 ± 11.43                         −0.119                0.906                  0.804                 0.423            0.595     0.553
  EDV (ml)               109.64 ± 14.56                     110.72 ± 14.49                        −0.751                0.456                  −1.021                0.310            −0.958    0.340
  ESV (ml)               43.17 ± 6.92                       43.11 ± 8.12                          0.074                 0.942                  −0.913                0.364            −0.676    0.501
  SV (ml)                66.47 ± 8.91                       67.60 ± 8.29                          −1.273                0.209                  −0.887                0.377            −1.042    0.300
  EF (%)                 60.56 ± 2.59                       61.00 ± 3.56                          −1.123                0.267                  0.461                 0.646            −0.063    0.950
  FS (%)                 34.28 ± 5.28                       34.07 ± 4.60                          0.436                 0.665                  −0.198                0.843            −0.638    0.525
                                                                                                                                                                                                
  **Items**              **AM Group 1 versus AM Group 2**   **Control group versus AM Group 2**                                                                                                 
                                                                                                                                                                                                
  **Before treatment**   **After treatment**                **Before treatment**                  **After treatment**                                                                           
                                                                                                                                                                                                
  ***t***                ***P***                            ***t***                               ***P***               ***t***                ***P***               ***t***          ***P***   
                                                                                                                                                                                                
  LAd (mm)               −0.202                             0.841                                 0.247                 0.805                  −1.955                0.053            −1.162    0.248
  LVEDd (mm)             0.100                              0.921                                 −0.797                0.428                  0.381                 0.704            −1.037    0.302
  LVESd (mm)             1.671                              0.098                                 0.330                 0.742                  1.954                 0.053            0.786     0.433
  IVST (mm)              −0.281                             0.779                                 −0.564                0.574                  0.520                 0.604            0.645     0.520
  LVPWT (mm)             −0.454                             0.651                                 0.240                 0.811                  0.333                 0.740            0.686     0.494
  LVM (g)                −0.346                             0.730                                 −0.513                0.609                  0.651                 0.516            0.162     0.872
  LVMI (g/m^2^)          0.281                              0.780                                 −0.211                0.834                  1.073                 0.286            0.388     0.699
  EDV (ml)               −0.504                             0.615                                 −0.196                0.845                  −1.479                0.142            −1.116    0.267
  ESV (ml)               −0.154                             0.878                                 0.219                 0.827                  −1.098                0.275            −0.413    0.681
  SV (ml)                −0.695                             0.489                                 −0.565                0.573                  −1.563                0.121            −1.533    0.128
  EF (%)                 −0.153                             0.878                                 −0.597                0.552                  0.329                 0.743            −0.714    0.477
  FS (%)                 −1.697                             0.093                                 −0.756                0.451                  −1.731                0.086            −1.423    0.158

The data were shown as mean ± SD. LAd: Left atrial diameter; LVEDd: Left ventricular end-diastolic dimension; LVESd: Left ventricular end-systolic dimension; IVST: Interventricular septal thickness; LVPWT: Left ventricular posterior wall thickness; LVM: Left ventricular mass; LVMI: Left ventricular mass index; EDV: End-diastolic volume; ESV: End-systolic volume; SV: Stroke volume; EF: Ejection fraction; FS: Fractional shortening; SD: Standard deviation; AM: *Astragalus membranaceus*.

The patients in the three groups did not have significant differences in LVEDd, IVST, LVPWT, LVM, LVMI, LA, LVESd, EDV, ESV, SV, EF, and FS levels between baseline and 12 months after treatment (all *P* \> 0.05).

Diastolic function analyses {#sec2-14}
---------------------------

With regard to the levels of diastolic function, patients in AM Group 2 had significantly higher E' (0.065 ± 0.007 vs. 0.061 ± 0.008, *P* = 0.014), E/A (0.81 ± 0.05 vs. 0.80 ± 0.06, *P* = 0.012), and E'/A' (0.56 ± 0.12 vs. 0.51 ± 0.13, *P* = 0.048), but lower E/E' (10.70 ± 1.30 vs. 11.37 ± 1.73, *P* = 0.031), than those in the control group at 12 months after treatment. However, among the three groups, E, A, DT, A', propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all *P* \> 0.05; [Table 4](#T4){ref-type="table"}).

###### 

Comparisons of left ventricular diastolic function among three groups before and after treatments

  Items                  Control group (*n* = 52)           AM Group 1 (*n* = 49)                                                                                                               
  ---------------------- ---------------------------------- ------------------------------------- --------------------- ---------------------- --------------------- ---------------- --------- -------
  E (m/s)                0.67 ± 0.03                        0.68 ± 0.04                           1.023                 0.311                  0.67 ± 0.03           0.68 ± 0.05      --0.164   0.871
  A (m/s)                0.85 ± 0.04                        0.85 ± 0.03                           --0.124               0.902                  0.84 ± 0.04           0.83 ± 0.03      --1.377   0.175
  E/A                    0.79 ± 0.04                        0.80 ± 0.06                           1.749                 0.086                  0.80 ± 0.04           0.81 ± 0.06      1.464     0.150
  DT (ms)                276.60 ± 51.41                     274.46 ± 36.35                        0.440                 0.662                  268.45 ± 56.19        266.57 ± 46.27   0.430     0.669
  E' (m/s)               0.060 ± 0.010                      0.061 ± 0.008                         --0.409               0.684                  0.062 ± 0.009         0.062 ± 0.009    0.280     0.781
  A' (m/s)               0.120 ± 0.018                      0.123 ± 0.017                         --1.044               0.301                  0.119 ± 0.020         0.122 ± 0.019    --1.272   0.210
  E'/A'                  0.51 ± 0.11                        0.51 ± 0.13                           0.227                 0.822                  0.54 ± 0.13           0.52 ± 0.14      1.079     0.286
  E/E'                   11.49 ± 1.90                       11.37 ± 1.73                          1.003                 0.321                  11.04 ± 1.60          11.18 ± 1.66     --0.241   0.811
  Vp (cm/s)              0.51 ± 0.06                        0.50 ± 0.07                           0.190                 0.850                  0.50 ± 0.07           0.50 ± 0.07      --0.181   0.857
  Ar (cm/s)              25.90 ± 5.68                       26.44 ± 4.75                          --1.236               0.222                  25.96 ± 6.06          26.65 ± 4.65     --1.604   0.115
  E/Vp                   1.65 ± 0.21                        1.65 ± 0.24                           --0.042               0.974                  1.67 ± 0.24           1.66 ± 0.22      0.263     0.779
                                                                                                                                                                                                
  **Items**              **AM Group 2 (*n* = 53)**          **Control group versus AM Group 1**                                                                                                 
                                                                                                                                                                                                
  **Before treatment**   **After treatment**                ***t***                               ***P***               **Before treatment**   **After treatment**                              
                                                                                                                                                                                                
  ***t***                ***P***                            ***t***                               ***P***                                                                                       
                                                                                                                                                                                                
  E (m/s)                0.68 ± 0.03                        0.68 ± 0.05                           0.685                 0.497                  −0.332                0.741            −1.105    0.272
  A (m/s)                0.86 ± 0.03                        0.85 ± 0.05                           1.304                 0.198                  0.747                 0.457            −0.485    0.629
  E/A                    0.80 ± 0.04                        0.81 ± 0.05                           --0.765               0.448                  −1.017                0.311            −1.037    0.302
  DT (ms)                268.74 ± 53.87                     261.49 ± 44.41                        2.047                 0.046                  0.761                 0.449            0.956     0.341
  E' (m/s)               0.062 ± 0.008                      0.065 ± 0.007                         --1.906               0.062                  −1.192                0.215            −0.741    0.436
  A' (m/s)               0.124 ± 0.020                      0.119 ± 0.021                         1.648                 0.105                  0.325                 0.746            0.122     0.903
  E'/A'                  0.52 ± 0.13                        0.56 ± 0.12                           --2.418               0.019                  −1.188                0.246            −0.583    0.549
  E/E'                   11.24 ± 1.56                       10.70 ± 1.30                          2.377                 0.021                  1.293                 0.180            0.353     0.711
  Vp (cm/s)              0.49 ± 0.06                        0.48 ± 0.05                           1.047                 0.300                  0.234                 0.815            0.042     0.967
  Ar (cm/s)              26.70 ± 6.05                       26.85 ± 4.50                          --0.349               0.728                  −0.047                0.962            −0.225    0.822
  E/Vp                   1.73 ± 0.22                        1.73 ± 0.20                           --0.149               0.877                  −0.440                0.661            −0.283    0.778
                                                                                                                                                                                                
  **Items**              **AM Group 1 versus AM Group 2**   **Control group versus AM Group 2**                                                                                                 
                                                                                                                                                                                                
  **Before treatment**   **After treatment**                **Before treatment**                  **After treatment**                                                                           
                                                                                                                                                                                                
  ***t***                ***P***                            ***t***                               ***P***               ***t***                ***P***               ***t***          ***P***   
                                                                                                                                                                                                
  E (m/s)                −1.400                             0.165                                 −0.190                0.849                  −1.765                0.081            −1.362    0.176
  A (m/s)                −1.502                             0.136                                 0.960                 0.339                  −0.806                0.422            0.631     0.530
  E/A                    0.410                              0.683                                 −1.262                0.210                  −0.650                0.517            −2.564    0.012
  DT (ms)                −0.026                             0.979                                 0.566                 0.573                  0.765                 0.446            1.636     0.105
  E' (m/s)               0.316                              0.761                                 −1.666                0.096                  −0.966                0.339            −2.653    0.014
  A' (m/s)               −1.161                             0.248                                 0.768                 0.444                  −0.906                0.367            0.938     0.350
  E'/A'                  0.883                              0.358                                 −1.355                0.175                  −0.257                0.803            −2.074    0.048
  E/E'                   −0.558                             0.603                                 1.834                 0.078                  0.825                 0.400            2.228     0.031
  Vp (cm/s)              1.210                              0.229                                 1.892                 0.061                  1.559                 0.122            1.893     0.061
  Ar (cm/s)              −0.616                             0.539                                 −0.216                0.829                  −0.693                0.490            −0.450    0.653
  E/Vp                   −1.319                             0.190                                 −1.652                0.102                  −1.901                0.060            −1.878    0.063

The data were shown as mean ± SD. E: Early diastolic mitral peak flow velocity; A: Late diastolic mitral peak flow velocity; DT: Deceleration time; E': Early diastolic mitral annular velocity; A': Late diastolic mitral annular velocity; Vp: Propagation velocity; Ar: Atrial reversal velocity; SD: Standard deviation; AM: *Astragalus membranaceus*.

Indicators of diastolic function, including E, A, E/A, DT, E', A', Vp, Ar, E/E', E'/A', and E/Vp, were similar between baseline and 12 months after treatment in the control group and AM Group 1 (all *P* \> 0.05). In AM Group 2, there were no statistically significant differences between baseline and 12 months after treatment in terms of E, A, E/A, E', A', Vp, Ar, and E/Vp (all *P* \> 0.05).

However, in AM Group 2, DT, E'/A', and E/E' all significantly improved 12 months after treatment, compared with baseline \[[Table 4](#T4){ref-type="table"}\].

Multiple linear regression analysis {#sec2-15}
-----------------------------------

There were significant correlations between several parameters of MetS and the diastolic function of the patients in AM Group 2. In the final multiple regression models, after model adjustment for age, SBP, and DBP, four metabolism-related indicators remained significantly associated with several diastolic function indices. WC was positively correlated with E' (*r* = 0.472; *P* = 0.003) and E'/A' (*r* = 0.321; *P* = 0.047). WHR was positively correlated with DT (*r* = 0.276; *P* = 0.041) and E/E' (*r* = 0.454; *P* = 0.004) and inversely correlated with E' (*r* = −0.590; *P* \< 0.001) and E'/A' (*r* = −0.377; *P* = 0.018).

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

MetS is a concept that draws attention to complex multifactorial health problems.\[[@ref4]\] The prevalence of MetS remains significantly increased in postmenopausal women, and the risk of MetS increases with postmenopausal stage, even after adjusting for possible confounding factors.\[[@ref20]\] Therefore, this study paid more attention to the MetS and relative target organ damages of postmenopausal women. Menopause is characterized by the natural cessation of menstruation; and during this time, there is a dramatic decline in the production of ovarian hormones, especially estrogen.\[[@ref21]\] The enrolled patients were all postmenopausal women whose metabolic changes were a decrease in estrogen level and an increase in abdominal visceral fat.\[[@ref22]\] That is to say, in postmenopausal women with MetS, the protective effects of estrogen may be lacking, and higher testosterone may be present due to increased adiposity. Estrogen could induce vascular relaxation by stimulating the release of endothelium-derived vasodilatory substances or by acting directly on vascular smooth muscle.\[[@ref23][@ref24]\] Equol might protect against CVD by increasing the transcription of endothelial nitric oxide (NO) synthase and increasing the levels of NO, a vasodilator that might lower blood pressure.\[[@ref25]\] However, testosterone favors visceral fat accumulation and an inflammatory pattern in women, thus possibly enhancing an increasing intrinsic blood pressure trend.\[[@ref26]\]

The increased prevalence of EH postmenopause in population surveys is well known. EH, as one of the components of MetS, is a major cardiovascular risk factor possibly explaining the excessive cardiovascular morbidity and mortality in postmenopausal women. Moreover, EH conveyed a 4-fold risk of CVD compared to normotensive women.\[[@ref27]\] Many of the other features of MetS (increased TG, reduced HDL-c, increased BP, increased FPG, and central obesity) appeared with estrogen deficiency in postmenopausal women.\[[@ref28]\] Each of them was related to an increased risk of atherosclerosis, arterial stiffness, and CVD.\[[@ref29]\] Therefore, a decline in sex hormone levels might contribute to the increased cardiovascular risk and MetS occurrence in postmenopausal women.\[[@ref30]\]

On the other hand, a previous study reported that a higher inflammatory status (evaluated by vascular cell adhesion molecule-1, E-selectin, interleukin (IL)-6, and C-reactive protein) and a higher level of oxidative stress were independently associated with MetS.\[[@ref31][@ref32]\] For women, after the onset of menopause, weight gain and changes in body fat distribution are frequent.\[[@ref33]\] Adipose tissue is an active endocrine and paracrine organ that releases a large number of cytokines and bioactive mediators, such as leptin, adiponectin, IL-6, and tumor necrosis factor, that negatively influence glucose and lipid homeostasis, blood pressure, coagulation, fibrinolysis, and inflammation, potentially leading to endothelial dysfunction and atherosclerosis.\[[@ref34]\] Moreover, considering the above conclusions, the results of this study similarly suggested the important roles of WC and WHR in the diastolic function in postmenopausal hypertensive women with MetS. The results were in agreement with other previous studies, which reported that abdominal obesity was reported to be associated with insulin resistance, inflammation, altered cytokine profiles, and endothelial dysfunction, this explained why WC is such a strong predictor of CVD.\[[@ref31]\] Therefore, body weight and distribution of adipose tissue are of considerable importance in clinical diagnosis and should become targets for intervention.

Some studies suggested that, based on the above pathomechanism, the target organ damages were frequent. For the cardiac tissue damage, LVDD was more prevalent and earlier in postmenopausal women.\[[@ref35]\] Therefore, early diagnosis and treatment of LVDD might be useful to reduce morbidity and improve the outcomes.\[[@ref36]\] LVDD refers to mechanical and functional abnormalities during relaxation and filling of the ventricle. Hence, LV diastolic filling might be abnormal even in the absence of LV hypertrophy and might represent an early marker of hypertension-related heart disease in EH. Some previous investigations have shown a sharp decrease in LV diastolic function in healthy women after 50--60 years of age, compared with men, suggesting that menopause might accelerate.\[[@ref37][@ref38]\] Moreover, postmenopausal state might be the independent and important risk factor for LVDD, although the LVDD of postmenopausal hypertensive women was affected by metabolic disorders.\[[@ref39]\] Several animal studies have suggested that estrogen loss by ovariectomy-induced cardiomyocyte hypertrophy and cardiac fibrosis were important processes that contributed to LVDD.\[[@ref35]\] In other previous studies, overwhelming evidences from clinical and basic research have implicated that an activated circulating and tissue renin-angiotensin-aldosterone system (RAAS), increased angiotensin II, and production of reactive oxygen species would aggravate LVDD and perivascular fibrosis in postmenopausal hypertensive women.\[[@ref40][@ref41]\] Mounting evidences indicated that estrogen also regulated other components of the RAAS, such as angiotensinogen, renin, tissue angiotensin II Type 1 and 2 receptors (AT~1~R and AT~2~R, respectively), and aldosterone production.\[[@ref42]\] Moreover, chronic activation of the RAAS increased oxidative stress and reduced NO bioavailability in estrogen-sensitive tissues, leading to endothelial dysfunction,\[[@ref43]\] inflammation,\[[@ref44]\] and immune dysfunction.\[[@ref45]\] These findings could be easily explained by increased aortic stiffness and high peripheral resistance, which compromised LV diastolic function in postmenopausal women.\[[@ref36]\] Each of these processes was associated with obesity, diabetes, renal disease, and EH, which are all diseases characterized by reductions in myocardial relaxation and LV compliance.\[[@ref35]\] In addition, there are other determinants of LVDD. A recent study has found a strong correlation between LVDD and hypercholesterolemia in a population of postmenopausal women affected by a mild-moderate EH.\[[@ref46]\]

From the results of this study and other previous studies, it could be found that postmenopausal women had more pathological changes, which made the target organ damage more frequent. Therefore, this kind of patients should be paid more attention. The prevention and treatment of MetS are important in reducing cardiovascular morbidity and mortality. EH is a major risk factor for stroke, coronary heart disease, heart failure, and renal disease.\[[@ref47]\] Data from epidemiologic studies have indicated that the successful control of blood pressure was achieved in only a low percentage of the hypertensive population.\[[@ref48]\] Moreover, MetS was frequently accompanied by endothelial dysfunction and increased blood pressure.\[[@ref49]\]

AM is a traditional Chinese medicine. It is a widely used herbal material in traditional Chinese medicine. The main active components include astragaloside, isoflavones, saponins, polysaccharides, and flavonoids\[[@ref50]\] and have been shown to significantly lower high blood glucose and triglyceride levels, improve impaired glucose tolerance, and increase insulin sensitivity.\[[@ref51]\] AM has long been recognized to possess antihypertensive, anti-inflammatory, antioxidant, anti-infarction, anti-nociceptive, lipid-modifying, antiallergic, hepatoprotective, renal protective, antithrombotic, wound-healing, cardioprotective, neuroprotective, antiviral, and anticarcinogenic activities.\[[@ref52]\] These effects may need long time of treatment to become significant. Moreover, AM could enhance myocardial contractility, improve circulation, protect myocardial cells, and protect against ischemic brain injury.\[[@ref53]\]

CVD was associated with endothelial dysfunction and decreased production and bioavailability of NO. Recent studies suggested that an important mechanism by which AM improved vascular health was through its effects on NO status.\[[@ref54]\] Previous studies have indicated improvement in the endothelial function with an increased production of NO and cyclic guanosine monophosphate (cGMP) production in the myocardium and aorta following AM treatment. That is to say, AM might improve endothelium-dependent vessel relaxation partly via its effects on the NO/cGMP pathway. In addition, increased inflammation might be an important factor contributing to the development of MetS.\[[@ref55]\] Importantly, the cardioprotective effects of AM might be associated with its antioxidant, antiapoptotic, and anti-inflammatory activities.\[[@ref52]\] Mao *et al*.\[[@ref56]\] have indicated that the systolic and diastolic functions could be improved by AM treatment in rats. Combined with the findings mentioned above, this study also suggested that AM might improve the diastolic function of postmenopausal hypertensive women with MetS through the effects of antioxidant, anti-inflammatory, and endothelial protection in shorter treatment time. Furthermore, these improvements were dose-dependent. In addition, WC and WHR were risk factors of LVDD in postmenopausal hypertensive women with MetS. That is to say, if the time of treatment is extended, the LVDD might be further improved through the regulation of AM on metabolic disorders.

In conclusion, this study could provide evidence that for postmenopausal hypertensive women with MetS, AM might improve LVDD in a dose-dependent manner. In these patients, WC and WHR were independently associated with an increased risk of LVDD. WC was positively associated with E' and E'/A'. WHR was positively associated with DT and E/E' and inversely correlated with E' and E'/A'.
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